Device Trial Radar · NCT05999851
Multiparametric Assessment of Maternal Vascular Function in the Prediction of Hypertensive Disorders of Pregnancy
Last checked: Nov 20, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Sep 1, 2023
Primary completion
May 2026
Study completion Sep 2031
Sponsor
- Lead sponsor
- IRCCS Azienda Ospedaliero-Universitaria di BolognaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Bologna
- First posted
- Aug 21, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated device
- Yes
- Who can join
- Female only, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The present study is a single-centre prospective study that will enrol pregnant women during their first trimester of pregnancy (11+0 - 13+6 weeks of gestation). During pregnancy, women will undergo standard clinical evaluation and management. During the two study visits (enrollment and 24+0 - 27+6 weeks of gestation) the investigators will perform arterial tonometry (Pulsepen) and in vivo darkfield microscopy (Glycocheck) to evaluate endothelial and vascular function. A urine sample and a blood sample for specific study analyses on metabolic profile, endothelial and angiogenic markers will be collected. Pregnancy outcomes will be collected at delivery and five years after delivery all the participants will be interview to collect long-term cardiovascular outcomes. Serum endothelial and angiogenic markers will be evaluated only in participants who will develop hypertensive disorders of pregnancy and in an equal number of controls matched for age and body mass index at the time of conception.
Conditions
- Preeclampsia
- Hypertensive Disorder of Pregnancy
Interventions
Arterial applanation tonometryDevice
Arterial applanation tonometry will be performed at the carotid and femoral level by the PulsePen device (Software WPulsePen version 2.3.1, DiaTecne, Milan, Italy), while the subject is lying in the horizontal position and after 5 minutes of rest.
In vivo endothelial glycocalyx measurementDevice
The in vivo microscopy (GlycoCheck system) is performed in the sublingual capillaries during the morning, with the participant sitting on a chair. The sublingual capillaries are visualized using an SDF video microscope (Capiscope handheld, KK Research technology Ltd).
Serum markers of angiogenesis and endothelial dysfunctionDiagnostic test
ELISA assays to measure serum circulating markers of angiogenesis and endothelial dysfunction (ANG-1, ANG-2, ET-1, ICAM-1 and VCAM-1).
Blood chemistry testDiagnostic test
Immunochemistry analysis of serum levels of uric acid, total cholesterol, LDL-cholesterol, HDL-cholesterol, Triglycerides, Lipoprotein (a)
Serum xanthine oxidase activityDiagnostic test
Serum xanthine oxidase (XO) activity will be assessed in blood samples measuring the ability of XO to produce uric acid
Primary outcomes
What the sponsor says the trial is designed to measure.
- Perfused Boundary Region (PBR)Time frame: Baseline visit (11/13+6 weeks of pregnancy)
- Perfused Boundary Region (PBR)Time frame: Follow-up visit (24/27+6 weeks of pregnancy)
- Carotid-femoral pulse wave velocity (cf-PWV)Time frame: Baseline visit (11/13+6 weeks of pregnancy)
3 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cardiovascular Internal Medicine Unit, IRCCS University Hospital of Bologna, Bologna, Italy
Bologna, Italy · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.